Trial Profile
Pharmacokinetic Study of the HCV Protease Inhibitor BocePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Omeprazole
- Indications Dyspepsia; Gastro-oesophageal reflux; Helicobacter pylori infections; Hepatitis C; Peptic ulcer; Zollinger-Ellison syndrome
- Focus Pharmacokinetics
- Acronyms PROMO
- 21 May 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Nov 2011 New trial record